China Biotech Weekly #15: The WuXi Question — Mapping the Supply Chain Exposure That 79% of US Biotechs Share

This Week's Top Takeaway

79% of US biotechs have at least one contract with a WuXi entity — and most compliance teams don't know which specific WuXi subsidiary they contract with. This matters because BIOSECURE Category C designates subsidiaries, parents, and successors of BCCs. If any WuXi entity is designated under Category B, the cascade through the WuXi group's complex holding structure could affect contracts that appear to be with "different" companies. Map your exposure at the entity level, not the brand level.

Alternative CDMO Strategies

For organizations building BIOSECURE contingency plans, the alternative CDMO landscape breaks down by service type:

Small molecule CDMO alternatives: Lonza, Catalent (now Novo Holdings), Thermo Fisher, Samsung Biologics, Siegfried, Cambrex. Capacity exists but lead times are 6-12 months longer than WuXi for new programs. Cost premium: 20-40% over WuXi for comparable services. Biologics CDMO alternatives: Samsung Biologics (Korea), Fujifilm Diosynth, Lonza, Boehringer Ingelheim BioXcellence. The biologics CDMO market is tighter than small molecule — capacity constraints could last through 2028 if WuXi Biologics is designated. ADC conjugation alternatives: Lonza, Novasep, Piramal Pharma, MabPlex (China — potential BIOSECURE exposure TBD). ADC manufacturing is the most constrained segment — fewer providers, more specialized equipment, and longer tech transfer timelines. The practical reality: A full transition away from WuXi takes 18-24 months for an active clinical program, including tech transfer, analytical method validation, and regulatory filing amendments. Organizations that wait for BCC designation to begin planning will face capacity constraints and timeline delays that could push back clinical milestones by 12+ months.

BIOSECURE Watch

Status: 🟡 New Development Key development: Two Am Law 100 firms (Ropes & Gray and Hogan Lovells) published updated BIOSECURE client advisories this week, both emphasizing the Category C subsidiary cascade risk. Both advisories recommend that clients map their WuXi exposure at the entity level — not just "we use WuXi" but "we contract with WuXi Biologics (Wuxi) Co., Ltd." versus "WuXi AppTec (Shanghai) Co., Ltd." The distinction may determine whether individual contracts fall within or outside a potential BCC designation scope. SEC disclosure update: One additional public company filed BIOSECURE risk factor language in its 10-K this week, bringing the running total to approximately 16. The new filer is a mid-cap oncology company with clinical-stage ADC programs manufactured at WuXi XDC facilities.

CDE Filing Watch

WuXi Biologics filed regulatory documentation with CDE for a process improvement at its Wuxi manufacturing facility. While this is a routine manufacturing filing, it's notable because it confirms WuXi Biologics continues to invest in Chinese manufacturing capacity — suggesting the company is not planning a wholesale pivot away from China-based production despite BIOSECURE uncertainty.

BeiGene (百济神州) received CDE approval for a manufacturing supplement for zanubrutinib at its own Guangzhou facility. BeiGene's in-house manufacturing capability is increasingly relevant as a differentiator — companies with their own manufacturing are insulated from CDMO-related BIOSECURE risk.

Takeaways for BD Teams

Map your WuXi exposure at the entity level. "We use WuXi" is not sufficient for BIOSECURE compliance planning. Which specific subsidiary? What's its corporate relationship to WuXi AppTec? Is it a wholly-owned subsidiary, a partially spun-off listed entity, or an operational division?

Start alternative CDMO conversations now, even if you don't switch. Having a qualified backup CDMO with completed tech transfer feasibility assessment is a strategic asset. It takes 18-24 months to fully transition — you cannot wait for BCC designation.

Companies with in-house manufacturing have a structural advantage. BeiGene, Hengrui, and Legend Biotech manufacture their own products. For BD teams evaluating China-origin assets, asking "who manufactures this?" is now as important as asking "what's the Phase III data?"

Watch the Category C interpretation closely. If OMB defines "subsidiary" broadly to include partially spun-off, separately listed entities, the WuXi XDC IPO strategy may not achieve the structural isolation its architects intend. This is the single most consequential definitional question in BIOSECURE implementation.

China Biotech Weekly is published every Thursday. For questions, tips, or deal intelligence, reach out at antony@chinabiointel.com. — Antony Tan